openPR Logo
Press release

Alport Syndrome Market Is Expected To Grow During the Study Period (2019-2032), DelveInsight | Key Companies- Reata Pharmaceuticals, Regulus Therapeutics/ Sanofi Genzyme, and Several Others

09-22-2022 02:35 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Alport Syndrome Market

Alport Syndrome Market

"The increase in Alport Syndrome Market size is a direct consequence of an increase in R&D activity, increasing prevalent population, expected commercial success of upcoming therapies in the 7MM"

The potential drugs recently launched in Alport Syndrome Market or expected to get launched in the market during the study period 2019-2032.
The Alport Syndrome market report provides current treatment practices, emerging drugs, Alport Syndrome market share of the individual therapies, current and forecasted Alport Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Alport Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Alport Syndrome market.

Key highlights of the Alport Syndrome Market Research Report
• According to DelveInsight, the Alport Syndrome Market in 7MM is expected to witness a major change in the study period 2019-2032
• According to the Clinical Journal of American Society of Nephrology, Alport Syndrome is an inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities. Inheritance is X-linked (85%) or autosomal recessive (15%). Alport syndrome primarily affects men. However, twice as many women are affected by the X-linked diseases. Affected women are commonly undiagnosed, but 15%-30% develop renal failure by 60 years and often hearing loss by middle age.
• According to National Organization for Rare Disorders (NORD) 2019, Alport Syndrome is estimated to affect approximately 1 in 5,000-10,000 people in the general population in the United States, which means that approximately 30,000-60,000 people in the United States have the disorder.
• According to the US National Library of medicine 2019, Alport syndrome occurs in approximately 1 in 50,000 newborns

Discover which therapies are expected to grab major Alport Syndrome Market Report @ https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alport Syndrome Overview
Alport Syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with Sensorineural hearing loss and ocular abnormalities. Patients with Alport Syndrome will experience progressive loss of kidney function. Almost all patients experience blood in their urine (hematuria) as well as proteinuria at symptom onset. The kidneys lose function as this condition progresses, resulting in kidney failure.

Alport Syndrome Epidemiology Insights
Males and females are often not equally affected, but males tend to be more badly affected, while females may only ever have blood and protein in urine, and possibly high blood pressure. A few females, however, will develop CKD, usually in later life. Significant hearing loss, eye abnormalities, and progressive kidney disease are more common in males with Alport Syndrome than in affected females.

Alport Syndrome Epidemiology Segmentation in the 7MM
• Total Alport Syndrome Prevalent Population
• Alport Syndrome Age-specific Prevalent Cases
• Alport Syndrome Sex-specific Prevalence
• Alport Syndrome Type-specific Prevalence
• Alport Syndrome Diagnosed and Treatable Cases

Alport Syndrome Treatment Market
The Alport syndrome treatment is directed toward the specific symptoms that are apparent in each individual. Medications known as angiotensin-converting enzyme (ACE) inhibitors have been used to treat individuals with Alport syndrome. This off-label use may not be appropriate for all affected individuals and several factors must be considered before starting the therapy such as baseline kidney function, family history, and specific symptoms present. ACE inhibitors may be given when elevated levels of protein are detectable in the urine (overt proteinuria) in certain cases. These drugs are blood pressure medications that prevent (inhibit) an enzyme in the body from producing angiotensin II. Angiotensin II is a chemical that acts to narrow blood vessels and can raise blood pressure.

Download the report to understand which factors are driving Alport Syndrome Market @ https://www.delveinsight.com/report-store/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alport Syndrome Market Insight
Loss of hearing is likely to be permanent, but affected individuals can be assisted with hearing aids. Counseling and education to increase coping skills can be helpful. Learning new skills such as lip reading or sign language may be of some benefit. Young men with Alport syndrome should use hearing protection in noisy environments. Genetic counseling may be recommended to explain the inherited pattern of the disorder.

Major Alport Syndrome Treatment Options
Treatment for other aspects of the condition are addressed as needed. For instance, surgical repairs of the eye manifestations may be recommended. Loss of hearing is likely to be permanent, but affected individuals can be assisted with hearing aids. Counseling and education to increase coping skills can be helpful. Learning new skills such as lip reading or sign language may be of some benefit. Young men with Alport syndrome should use hearing protection in noisy environments. Genetic counseling may be recommended to explain the inherited pattern of the disorder.

Alport Syndrome Market Dynamics
The Alport Syndrome market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The key players such as Reata Pharmaceuticals/Sanofi Genzyme, Regulus Therapeutics have the potential to create a significant positive shift in the Alport Syndrome market Size. The current pipeline of Alport Syndrome is limited, as only few companies are working on Alport Syndrome. This provides an opportunity for other companies to enter the market and grab a significant market share.

To know more about the treatment for Alport Syndrome Market @ https://www.delveinsight.com/report-store/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis for Alport Syndrome
4. Alport Syndrome Market Overview at a Glance
5. Alport Syndrome Disease Background and Overview
6. Patient Journey
7. Alport Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Alport Syndrome Unmet Needs
10. Key Endpoints of Alport Syndrome Treatment
11. Alport Syndrome Marketed Products
12. Alport Syndrome Emerging Therapies
13. Alport Syndrome Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Alport Syndrome Market Outlook
16. Access and Reimbursement Overview of Alport Syndrome
17. KOL Views
18. Alport Syndrome Market Drivers
19. Alport Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Reach out for in-depth information of the Alport Syndrome Market Research Report @ https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alport Syndrome Market Is Expected To Grow During the Study Period (2019-2032), DelveInsight | Key Companies- Reata Pharmaceuticals, Regulus Therapeutics/ Sanofi Genzyme, and Several Others here

News-ID: 2744705 • Views:

More Releases from DelveInsight Business Research

Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Companies
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics. DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,

All 5 Releases


More Releases for Alport

Alport Syndrome Market is Expected to Reach $4.5 Billion by 2034
Alport syndrome is a rare genetic kidney disorder caused by mutations in the COL4A3, COL4A4, or COL4A5 genes, which affect the production of type IV collagen in the basement membranes of the kidneys, inner ear, and eyes. The condition leads to progressive renal disease, hearing loss, and ocular abnormalities, with most patients eventually developing kidney failure requiring dialysis or transplantation. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71647 Traditionally, treatment
Alport Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medication, …
Alport Syndrome companies are Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutics, Travere Therapeutics, Reata Pharmaceuticals, and others. Alport Syndrome Market Summary The Alport syndrome market in the 7MM was valued at around USD 20 million in 2023 and is projected to grow by 2034. The disorder is primarily X-linked, accounting for 80% of cases, with 90% of males progressing to kidney failure by age 40 if untreated. In 2023, the US
Alport Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatmen …
Alport Syndrome Pipeline constitutes 4+ key companies continuously working towards developing 6+ Alport Syndrome treatment therapies, analyzes DelveInsight. Alport Syndrome Overview: Alport syndrome is a rare inherited disorder, affecting approximately 1 in 50,000 people, and is most often characterized by microscopic hematuria and progressive chronic kidney disease (CKD), along with complications beyond the kidneys. The condition arises from mutations in the COL4A3, COL4A4, and COL4A5 genes, which interfere with the normal assembly
Alport Syndrome Market Size, Share, Trends, Industry Growth and Competitive Anal …
Data Bridge Market Research analyses a growth rate in the global alport syndrome market in the forecast period 2022-2029. Market Definition Alport syndrome is the rare, genetic, inherited X-linked disorder caused by the gene mutation of COL4A3, COL4A4, or COL4A5. It is a condition that damages the tiny blood vessels of the kidney, that leads to kidney damage & failure. It also causes hearing loss and eye abnormalities. Patients suffering from this
Novel Therapeutic Modalities Transforming the Alport Syndrome Treatment Market 2 …
According to the research report, the global alport syndrome treatment market was valued at USD 12.26 million in 2022 and is expected to reach USD 19.00 million by 2032, to grow at a CAGR of 4.5% during the forecast period. Polaris Market Research recently launched the latest update on Alport Syndrome Treatment Market: By Size, Trends, Share, Growth, Segments, Industry Analysis and Forecast, 2032 that gives an extensive outlook of the
Alport Syndrome Treatment Market Research Reports, Industry Size, Growth Opportu …
Polaris Market Research has recently published an insightful research study titled Alport Syndrome Treatment Market: By Size, Trends, Share, Growth, Segments, Industry Analysis and Forecast, 2032, providing a comprehensive analysis of the market structure based on usage and type. The report evaluates the Alport Syndrome Treatment Market size and share by conducting a thorough examination within a specific timeframe. With a focus on the market, the study delves into consumption